MTOR and hepatocellular carcinoma: In the vinorelbine-sensitive HCC PDX models (HCC19–0913 and HCC13–0109), the vinorelbine/mTOR-sensitive model (HCC13–0212), and the mTOR-sensitive model (HCC24–0309), everolimus/vinorelbine displayed from 1.5- to 10-fold increases in the percentage of cleaved PARP-positive cells, as well as significantly higher (from 1.5 to 2.5 fold) total blood-vessel counts compared with those of the vinorelbine and everolimus monotherapies (Figure 2 and Supplementary Figures S5, S6 and S11–S13).